12th Annual Controversies in Hematologic Malignancies Symposium

Milwaukee, WI US
February 11, 2023

Target Audience

Physicians, Physician Assistants, Nurse Practitioners, Registered Nurses and Allied Health Professionals

Learning Objectives

Participants who engage in this educational intervention will be able to: 

  • Identify current best practice evidence-based guidelines and novel treatment strategies for  FLT3 mutant AML.

  • Describe recommendations designed to improve immunotherapy treatment of multiple myeloma based on current advancements and trial results.

  • List challenges and treatment options for Non-Hodgkins Lymphoma in non-elderly patients based on updated guidelines.

Additional information

Contact

Name: 
Dan Bullock
Phone Number: 
+1 (414) 805-4617
Email: 
danbullock@mcw.edu
Course summary
Available credit: 
  • 4.25 AMA PRA Category 1 Credit(s)™
    AMA PRA Category 1 Credit(s)™
  • 4.25 Hours of Participation
    Hours of Participation credit.
Course opens: 
12/09/2022
Course expires: 
05/11/2023
Event starts: 
02/11/2023 - 8:00am CST
Event ends: 
02/11/2023 - 2:00pm CST
Cost:
$0.00
Add to calendar: 
Rating: 
0

AGENDA

7:30 – 8:25 a.m. Check in
8:25 – 8:30 a.m. Introduction
 
Lymphoma Block:
8:30 – 8:50 a.m. Updates in Treatment of Elderly Patients with Non-Hodgkins Lymphoma (NIRAV SHAH)  
8:50 – 9:30 a.m. Updates in Mantle Cell Lymphoma: What's Old is New and What's New is Old (JOHN LEONARD)
9:30 – 9:45 a.m. Panel Q&A with speakers (SHAH & LEONARD)
 
9:45 – 10:00 a.m. Break
 
Myeloma Block:
10:00 – 10:20 a.m. 2023 Updates in Light Chain Amyloidosis (ANITA D'SOUZA) 
10:20 – 11:00 a.m. Immunotherapy in Multiple Myeloma (SHAM MAILANKODY)
11:00 – 11:15 a.m. Panel Q&A with speakers (D'SOUZA & MAILANKODY)
 
11:15 – 11:30 a.m. Break
 
11:30 – Noon  Breakout Sessions:
  • Maintenance Strategies after Hematopoietic Cell Transplantation (LISA SAMANAS)
  • BMT Survivorship: The Need for Care Continues After Treatment Ends (RACHEL PHELAN)
  • Transitioning Inpatient Chemotherapy to the Outpatient Setting (MARY FOURNAGERAKIS)
12:00 – 12:45 p.m. Lunch
 
Leukemia Block:
12:45 – 1:05 p.m. CML: Not Cured Yet (MICHAEL DEININGER)
1:05 – 1:45 p.m. FLT3 Mutated AML (KEITH PRATZ)
1:45 – 2:00 p.m. Panel Q&A with speakers (DEININGER & PRATZ)
 
2:00 p.m. Adjourn

 

Hilton- Downtown Milwaukee
509 W. Wisconsin Ave.
Milwaukee, WI 53203
United States
+1 (414) 271-7250
Hilton Milwaukee City Center
In accordance with the ACCME® Standards for Integrity and Independence in Accredited Continuing Education, Standard 3, all in control of content must disclose any relevant financial relationships. The following in control of content had no relevant financial relationships to disclose.
 
Lisa Samanas, PharmD
Division of Hematology & Oncology
Froedtert Health
 
Mary Fournogerakis, BSN, RN, OCN
Division of Hematology & Oncology
Froedtert Health
 
Keith Pratz, MD
Director of Leukemia
Associate Professor of Medicine
Hospital of the University of Pennsylvania
 
Michael Deininger, MD
Mike & Cathy White Endowed Chair
EVP & Chief Scientific Officer
Blood Research Instititute, Versiti
Associate Dean of Research
Medical College of Wisconsin
 
 
The following persons in control of content disclosed the following financial relationships which were reviewed via the MCW conflict of interest mitigation process and addressed.
 
NameCompanyRole
Nirav Shah

Loxo Lilly and Miltenyi Biotech

Epizyme

Janssen, Kite Pharma, Incyte, Seattle Genetics, Novartis, BMS-Juno, TG Therapeutics, Tundra Therapeutics, Umoja

Consultant

Investigator

Advisory Board

Sham Mailankody

PleXus Education, Physician Education Resource, Cancer Network

Janssen Oncology, Bristol Myers Squibb and Fate Therapeutics

Evicore, Legend Biotech, BioAscend and Optum Oncology

Speaker

Investigator

Advisory Panel

Anita D'Souza

Bristol Myers Squibb, Prothena, Janssen Biotech

AbbVie, Caelum, Novartis, Regeneron, Sanofi, Takeda, TeneoBio

Consultant

Investigator

John P. Leonard
AbbVie, Astellas, AstraZeneca, Bayer, Beigene, Bristol Myers Squibb, Calithera, Constellation, Caribou Biosciences, Eisai, Lilly, Epizyme,
Genmab, Grail, Incyte, Janssen, MEI Pharma, Merck, Mustang Bio, Novartis, Pfizer, Roche, Genentech, Seagen, Second Genome,Sutro

Consultant

Rachel Phelan

Bluebird Bio

Amgen

Advisory Panel

Investigator

   

 

 

ACCME Accreditation Statement: 

The Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. 

AMA Credit Designation Statement: 

The Medical College of Wisconsin designates this for a maximum of 4.25 AMA PRA Category 1 Credit(s)™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Hours of Participation for Allied Health Care Professionals: 

The Medical College of Wisconsin designates this activity for up to 4.25 hours of participation for continuing education for allied health professionals.  

Available Credit

  • 4.25 AMA PRA Category 1 Credit(s)™
    AMA PRA Category 1 Credit(s)™
  • 4.25 Hours of Participation
    Hours of Participation credit.

Price

Cost:
$0.00
Please login or register to take this course.